Tag: research

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

PANAMA CITY, June 20, 2025 (GLOBE NEWSWIRE) -- Gate, a global leader in cryptocurrency trading, has released its May 2025 Transparency Report, revealing remarkable growth across key business indicators. Amid improving market sentiment and a maturing regulatory landscape, the platform recorded historic highs in trading volume and user activity, accelerated brand globalization efforts, advanced compliance achievements, and further expanded its Web3 ecosystem.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

シンガポール発, June 20, 2025 (GLOBE NEWSWIRE) -- 石油・ガス産業向けの地上型ウェルヘッドシステム (「SWS」) および油井管製品 (「OCTG」) を製造する成長志向の企業であるOMSエナジー・テクノロジーズ (「OMS」または「同社」) (NASDAQ: OMSE) は本日、2025年5月のナスダック上場成功後、初の決算発表を控える中で、直近の実績をまとめた事業アップデートを発表した。